ArticleScientific reports2025
DDTC-Cu(I) inhibits human osteosarcoma cells growth by repressing MET/PI3K/AKT signaling pathway.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Osteosarcoma (OS) is a frequently occurring bone malignancy with increased metastatic properties, causing deaths in large numbers around the world. Disulfiram (DSF) is clinically utilized to treat alcohol dependency and has been indicated to bind Cu(I) in-vivo to form DDTC-Cu(I), which has been confirmed for its antitumor effects. This investigation aimed to elucidate the efficacy of DDTC-Cu(I) on OS cell apoptosis, migration, growth, invasion, and underlying mechanisms. The in-vitro investigations were performed on U2OS, SaOS2, and MG-63 OS cell lines and included CCK-8, colony formation, RTCA, transwell invasion, flow cytometry, wound healing, and RNA seq assays. DDTC-Cu(I) was inoculated dose-dependent, increased apoptosis, and suppressed cells' ability to proliferate, migrate, and invade via the MET and PI3K/AKT signaling pathways. Additionally, MET's overexpression partially reversed the anti-OS and PI3K/AKT signaling pathways suppression effect of DDTC-Cu(I). Furthermore, the SaOS2 xenograft mice model was utilized to confirm the in-vivo anti-OS efficacy of DDTC-Cu(I) by MET protein inhibition. The histological research revealed that DDTC-Cu(I) had no adverse influence on the liver, heart, lungs, and kidneys. Overall, the data of this investigation suggested that DDTC-Cu(I) could serve as an efficient agent against OS development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.